Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

* Age ≥ 18 years * Karnofsky performance status (KPS) ≥ 70 * Histologically confirmed malignancy with the presence of one to four intraparenchymal brain metastases * Each patient must sign a study-specific Informed Consent form

* Previous cranial radiation * Complete resection of all known brain metastases * Known leptomeningeal metastases * Known liver metastases * Clinical or radiologic evidence of progression (other than study lesion\[s) within 1 month prior to enrollment * Patients with metastases within 10 mm of the optic apparatus * Patients with metastases in the brainstem, midbrain, pons, or medulla * Planned chemotherapy during WBRT and/or SRS * Uncontrolled hypertension * Women who are pregnant or lactating and Laboratory values as follows: * LDH \> 1.3 x upper limit of normal (ULN) * ANC \< 1500/mm3 * Platelets \< 50,000/mm3 * Creatinine \> 2.0 mg/dL * AST or ALT \> 3 x ULN * Total bilirubin \> 2 x ULN